{
    "clinical_study": {
        "@rank": "126000", 
        "acronym": "CENTERA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and device success of the Edwards CENTERA\n      Transcatheter Heart Valve (THV) System in patients with symptomatic, severe aortic stenosis\n      who are indicated for aortic valve replacement."
        }, 
        "brief_title": "Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Disease", 
        "detailed_description": {
            "textblock": "This is a non-randomized, prospective, multi-center safety and device success study. One\n      hundred fifty (150) patients are planned to be enrolled at up to 15 participating\n      investigational centers in Europe.  Patient participation will last for a minimum of 5\n      years.  Patients will be assessed at the following intervals: baseline, discharge, 30 days,\n      6 months, 1 year and annually thereafter through 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. High surgical risk: STS Score \u2265 8,EuroSCORE \u2265 15.\n\n          2. NYHA \u2265 II\n\n          3. AVA< 1cm2 and mean gradient > 40mmHg\n\n          4. Heart team (including examining cardiac surgeon) agrees on eligibility including\n             assessment that TAVR is appropriate\n\n          5. Study patient is an adult of legal consent age\n\n          6. Study patient has provided written informed consent to comply with all of the study\n             procedures and follow-up visits\n\n        Exclusion Criteria:\n\n          1. Acute myocardial infarction \u2264 30 days before the intended treatment\n\n          2. Untreated clinically significant coronary artery disease requiring revascularization.\n\n          3. Aortic valve is a congenital unicuspid or congenital bicuspid valve.\n\n          4. Mixed aortic valve disease (with predominant aortic regurgitation)\n\n          5. Preexisting bioprosthetic valve or ring in any position\n\n          6. Leukopenia, anemia, thrombocytopenia\n\n          7. Non-valvular hypertrophic cardiomyopathy with or without obstruction\n\n          8. Severe ventricular dysfunction with LVEF < 20%\n\n          9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation\n\n         10. Active upper GI bleeding within 30 days prior to procedure\n\n         11. Known contraindication or hypersensitivity to all anticoagulation regimens, or\n             inability to be anticoagulated for the study procedure\n\n         12. Native aortic annulus size < 18 mm or > 27 mm as measured by CT\n\n         13. Clinically (by neurologist) or neuroimaging confirmed stroke or TIA within 180 days\n             of the procedure\n\n         14. Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy at the\n             time of screening\n\n         15. Estimated life expectancy < 24 months\n\n         16. Expectation that patient will not improve despite treatment of aortic stenosis\n\n         17. Currently participating in an investigational drug or another device study\n\n         18. Active bacterial endocarditis within 180 days of procedure\n\n         19. Access vessel characteristics that would preclude safe placement of a 16F sheath,\n             which may include any of the following: severe obstructive calcification, severe\n             tortuosity\n\n         20. Known hypersensitivity to nitinol (nickel or titanium)\n\n         21. PCI within one month (30 days) prior to the TAVI procedure\n\n         22. Emergency procedures within one month (30 days) prior to the TAVI procedure.\n\n         23. Severe mitral insufficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808274", 
            "org_study_id": "2012-03"
        }, 
        "intervention": {
            "description": "The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).", 
            "intervention_name": "Edwards CENTERA Self-Expanding Transcatheter Heart Valve", 
            "intervention_type": "Device", 
            "other_name": [
                "TAVR", 
                "TAVI"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Transcatheter Aortic Valve Replacement", 
            "Aortic Stenosis"
        ], 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "grubee@aol.com", 
                    "last_name": "Eberhard Grube, MD", 
                    "phone": "+49 2241 146 1271"
                }, 
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53127"
                    }, 
                    "name": "Herzzentrum Universitaet Bonn"
                }, 
                "investigator": {
                    "last_name": "Eberhard Grube, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "k.kuck@asklepios.com", 
                    "last_name": "Karl-Heinz Kuck, MD", 
                    "phone": "+49 401818852305"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20099"
                    }, 
                    "name": "Asklepios Klinik St Georg Hamburg"
                }, 
                "investigator": {
                    "last_name": "Karl-Heinz Kuck, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mohrf@medizin.uni-Ieipzig.de", 
                    "last_name": "Friedrich Mohr, MD", 
                    "phone": "+49 341 865 1421"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "042 89"
                    }, 
                    "name": "Heart Center Leipzig"
                }, 
                "investigator": {
                    "last_name": "Friedrich Mohr, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Stephan.Windecker@insel.ch", 
                    "last_name": "Stephan Windecker, MD", 
                    "phone": "+41 31 632 4497"
                }, 
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "3010"
                    }, 
                    "name": "Inselspital Bern"
                }, 
                "investigator": {
                    "last_name": "Stephan Windecker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve", 
        "overall_contact": {
            "email": "jodi_akin@edwards.com", 
            "last_name": "Jodi Akin, MSN", 
            "phone": "949-250-2730"
        }, 
        "overall_contact_backup": {
            "email": "ihsen_merioua@edwards.com", 
            "last_name": "Ihsen Merioua, MD", 
            "phone": "+41 44 787 4456"
        }, 
        "overall_official": [
            {
                "affiliation": "Inselspital Bern (Switzerland)", 
                "last_name": "Prof. Windecker, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Leipzig, Rh\u00f6n Herzentrum (Germany)", 
                "last_name": "Prof. Mohr, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: BfArM (Federal Institute for Drugs and Medical Devices)", 
                "Switzerland: Swissmedic (Swiss Agency for Therapeutics Products)", 
                "France: ANSM (National Safety Agency for Drugs and Health Products)", 
                "Italy: Ministry Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "The Netherlands: IGZ (The Health Care Inspectorate)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "NAP", 
            "measure": "All-cause mortality rate", 
            "safety_issue": "Yes", 
            "time_frame": "30 days post-index procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808274"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "device success\nabsence of procedural mortality AND correct positioning of a single THV and intended performance of the THV\nsafety endpoints\ncomposite of mortality, and major complications including THV-related dysfunction major bleeds MI new conduction abnormality new onset of AF time-related valve safety compo-site of valve structural deterioration composite of all-cause mortality, all stroke, re-hospitalization for valve-related symptoms or worsening CHF rehospitalization for valve cause NYHA class 6 MWT QoL Hospital length of stay\nechocardiography endpoints\nPVL & total valve regurgitation prostetic valve dysfunction IEOA mean aortic valve gradient structural valve deterioration LVEF", 
            "measure": "device success (VARC II) safety endpoints (VARC II) echocardiography endpoints (VARC II)", 
            "safety_issue": "Yes", 
            "time_frame": "Discharge or 72 hours (whichever is longer), 30 days, 6 months, 1and 5 year post-index procedure."
        }, 
        "source": "Edwards Lifesciences", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Medstar Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "European Cardiovascular Research  Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of British Columbia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Edwards Lifesciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}